Fluticasone Propionate And Salmeterol Powder
Product Images NDC 68788-8704

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Fluticasone Propionate And Salmeterol (NDC 68788-8704). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figurec.jpg (Figurec)

FDA Label Image

Figuref.jpg (Figuref)

FDA Label Image

Figureh.jpg (Figureh)

FDA Label Image

Fluticasone-propionate-chemical.jpg (Fluticasone Propionate Chemical)

FDA Label Image

Figure-5-08172021.jpg (Image 03)

FDA Label Image

Figure-4.jpg (Image 04)

This description provides data on the effects of Fluticasone Propionate and Salmeterol Inhalation Powder compared to Salmeterol and Placebo in patients with baseline FEV of around 1205-1232 mL. The data shows measurements taken at different time points (weeks) during the study for each treatment group. The Fluticasone Propionate and Salmeterol Inhalation Powder group generally had higher measurements compared to the Salmeterol and Placebo groups.*

FDA Label Image

Figure-1a (Image 05)

This is a comparison of the effectiveness of Fluticasone Propionate and Salmeterol Inhalation Powder at a dose of 100 mcg/50 mcg twice daily, Fluticasone Propionate alone at 100 mcg twice daily, Salmeterol alone at 50 mcg twice daily, and a placebo. The table displays the percentage of participants with positive outcomes over a 12-week period, with the combined inhalation powder showing higher rates compared to the individual components and the placebo.*

FDA Label Image

Figure-2.jpg (Image 06)

This data shows the percentage change in FEV4 (Forced Expiratory Volume in 4 seconds) on the first treatment day for different groups using Fluticasone Propionate and Salmeterol Inhalation Powder, Salmeterol, Fluticasone Propionate, and Placebo. The graph displays the comparison over a 12-hour period, indicating the impact of each treatment on the participants' lung function.*

FDA Label Image

Figure-3a (Image 07)

FDA Label Image

Fluticasone Prop Salmeterol Inh Powder 100mcg50mcg (Image 09)

This text is from a pharmaceutical company cautioning against the transfer of a specific medication to anyone other than the prescribed patient. The mentioned drug is Fluticasone Propionate & Salmeterol Inhalation Powder with specific dosage information provided. The text also indicates that the medication is generic for Advair HFA. Additional details such as lot number, expiration date, and manufacturer information are included. The caution advises to keep the medication away from heat and sunlight, out of reach of children. For further information and directions, a patient leaflet is recommended.*

FDA Label Image

Image1.jpg (Image1)

This text appears to describe a product, likely a part or accessory. It includes references to an "Outer Case Counter," a "Thumb Grip," and a "Mouthpiece." These phrases suggest that the item might be related to a device or equipment that requires these components for operation or use.*

FDA Label Image

Salmeterol-xinafoate-chemical.jpg (Salmeterol Xinafoate Chemical)

FDA Label Image

Ww-image-2.jpg (Ww Image 2)

FDA Label Image

Ww-image-4.jpg (Ww Image 4)

FDA Label Image

Ww-image-5.jpg (Ww Image 5)

FDA Label Image

Ww-image-7.jpg (Ww Image 7)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.